ArticlePlastic and reconstructive surgery. Global open2026
Optimizing Pain Management in Autologous Breast Reconstruction: Intravenous Ketorolac in the Enhanced Recovery After Surgery Pathway.
Article in Plastic and reconstructive surgery. Global open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Enhanced recovery after surgery (ERAS) pathways can decrease hospital length of stay (LOS) and oral morphine equivalent (OME) use after autologous breast reconstruction. Ketorolac is a powerful nonsteroidal anti-inflammatory drug used in our ERAS pathway. The purpose of this study was to analyze the safety and efficacy of scheduled low- versus high-dose intravenous (IV) ketorolac. Methods: A retrospective study of patients who underwent abdominally based breast reconstruction with our ERAS protocol was conducted from July 2015 to June 2020. Controls (group A) received no IV ketorolac, whereas cases received at least 3 doses of either low-dose (15 mg, group B) or high-dose (30 mg, group C) IV ketorolac. Outcomes of interest included LOS, OME use, acute kidney injury, 30-day return to operating room, and blood transfusion. Results: A total of 159 patients were included (group A = 62, group B = 43, group C = 54). The 3 groups differed only in mean age (group A = 52.6 y, group B = 50.9 y, group C = 46 y; Conclusions: Scheduled postoperative ketorolac administration significantly reduces opioid consumption and LOS, without adverse effects, in patients undergoing abdominally based breast reconstruction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.